Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors

Blood

Volumn 100, Issue 12, 2002, Pages 4232-4233

  Simmelink, Marleen J A ^a,b,c   De Groot, Philip G ^a,b,c   Derksen, Ronald H W M ^a,b,c   Fernández, José A ^a,b,c   Griffin, John H ^a,b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; THROMBOSIS;

EID: 0036893548     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0329     Document Type: Article

References (18)

1. Gallus AS, Hirsh J. Antithrombotic drugs: Part I. Drugs. 1976;12:41-68.
2. Suttie JW. Mechanism of action of vitamin K: Synthesis of gamma-carboxyglutamic acid. Crit Rev Biochem. 1980;8:191-223.
3. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
4. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood. 1990;75:344-349.
5. Jones DW, Mackie IJ, Winter M, Gallimore M, Machin SJ. Detection of protein C deficiency during oral anticoagulant therapy - Use of the protein C:factor VII ratio. Blood Coagul Fibrinolysis. 1991;2:407-411.
6. Epstein DJ, Bergum PW, Bajaj SP, Rapaport SI. Radioimmunoassays for protein C and factor X: Plasma antigen levels in abnormal hemostatic states. Am J Clin Pathol. 1984;82:573-581.
7. Pabinger I, Allaart CF, Hermans J, Briet E, Bertina RM. Hereditary protein C-deficiency: Laboratory values in transmitters and guidelines for the diagnostic procedure: Report on a study of the SSC Subcommittee on Protein C and Protein S. Protein C Transmitter Study Group. Thromb Haemost. 1992;68:470-474.
8. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
9. Esmon CT, Xu J, Gu JM, et al. Endothelial protein C receptor. Thromb Haemost. 1999;82:251-258.
10. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 2001;97:1685-1688.
11. Stearns-Kurosawa DJ, Swindle K, D'Angelo A, et al. Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood. 2002;99:526-530.
12. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
13. Espana F, Vaya A, Mira Y, et al. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost. 2001;86:1368-1373.
14. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood. 1999;94:3839-3846.
15. Simmelink MJA, Fernández JA, Derksen RHWM, Griffin JH, De Groot PG. Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. Br J Haematol. 2002;117:676-684.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
17. Varadi K, Philapitsch A, Santa T, Schwartz HP. Activation and inactivation of human protein C by plasmin. Thromb Haemost. 1994;71:615-621.
18. Rezaie AR. Rapid activation of protein C by factor Xa and thrombin in the presence of polyanionic compounds. Blood. 1998;91:4572-4580.